Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | SUCNR1 | Q9BXA5 | 4/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.37 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.35 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.35 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9526858 | 0.97 | HDAC3 (0.38) | MAPTLMNAGAASUCNR1HDAC3 | |
| SCHEMBL2541499 | 0.97 | HDAC3 (0.38) | MAPTLMNAGAASUCNR1HDAC3 | |
| SCHEMBL10551133 | 0.95 | MAPT (0.39) | MAPTLMNAGAASUCNR1ACKR3 | |
| SCHEMBL10551124 | 0.95 | MAPT (0.39) | MAPTLMNAGAASUCNR1ACKR3 | |
| SCHEMBL9526816 | 0.88 | KMT2A (0.44) | MAPTLMNAGAASUCNR1HDAC3 | |
| SCHEMBL9526809 | 0.88 | KMT2A (0.44) | MAPTLMNAGAASUCNR1HDAC3 | |
| SCHEMBL9142511 | 0.88 | IDO1 (0.38) | MAPTLMNAGAAACKR3SIGMAR1 | |
| Methane SCHEMBL9366272 | 0.85 | MAPT (0.42) | MAPTLMNAGAA | |
| SCHEMBL10542795 | 0.85 | MAPT (0.43) | MAPTLMNAGAACA12CA1 | |
| SCHEMBL10542790 | 0.85 | MAPT (0.43) | MAPTLMNAGAACA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8557978-B2 | Cross-linked glycopeptide-cephalosporin antibiotics | THERAVANCE, INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-20120214967-A1 | CROSS-LINKED GLYCOPEPTIDE-CEPHALOSPORIN ANTIBIOTICS | THERAVANCE, INC. (US) | 2012-08-23 | — | — | US | disclosed |
| EP-1507796-B1 | CROSS-LINKED GLYCOPEPTIDE-CEPHALOSPORIN ANTIBIOTICS | THERAVANCE INC (US) | 2012-05-02 | — | — | EP | disclosed |
| US-8084417-B2 | Cross-linked glycopeptide-cephalosporin antibiotics | THERAVANCE, INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-8044195-B2 | Cross-linked glycopeptide-cephalosporin antibiotics | THERAVANCE, INC. (US) | 2011-10-25 | — | — | US | disclosed |
| US-20100197569-A1 | CROSS-LINKED GLYCOPEPTIDE-CEPHALOSPORIN ANTIBIOTICS | THERAVANCE, INC. (US) | 2010-08-05 | — | — | US | disclosed |
| US-7728127-B2 | Cross-linked glycopeptide-cephalosporin antibiotics | THERAVANCE, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| US-7713931-B2 | Cross-linked glycopeptide-cephalosporin antibiotics | THERAVANCE, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-7655621-B2 | Cross-linked glycopeptide-cephalosporin antibiotics | THERAVANCE, INC. (US) | 2010-02-02 | — | — | US | disclosed |
| US-7649080-B2 | Cross-linked glycopeptide-cephalosporin antibiotics | THERAVANCE, INC. (US) | 2010-01-19 | — | — | US | disclosed |
| US-6974797-B2 | Cross-linked glycopeptide-cephalosporin antibiotics | THERAVANCE, INC. (US) | 2005-12-13 | — | — | US | disclosed |
| US-20050239691-A1 | Cross-linked glycopeptide - cephalosporin antibiotics | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2005-10-27 | — | — | US | disclosed |
| US-20050209132-A1 | CROSS-LINKED GLYCOPEPTIDE-CEPHALOSPORIN ANTIBIOTICS | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2005-09-22 | — | — | US | disclosed |
| US-6878686-B2 | Cross-linked glycopeptide-cephalosporin antibiotics | THERAVANCE, INC. (US) | 2005-04-12 | — | — | US | disclosed |
| EP-1507796-A1 | CROSS-LINKED GLYCOPEPTIDE-CEPHALOSPORIN ANTIBIOTICS | Theravance, Inc. (US) | 2005-02-23 | — | — | EP | disclosed |
| EP-1434779-A2 | CROSS-LINKED GLYCOPEPTIDE-CEPHALOSPORIN ANTIBIOTICS | Theravance, Inc. (US) | 2004-07-07 | — | — | EP | disclosed |
| US-20040033939-A1 | Cross-linked glycopeptide-cephalosporin antibiotics | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2004-02-19 | — | — | US | disclosed |
| WO-2003099858-A1 | CROSS-LINKED GLYCOPEPTIDE-CEPHALOSPORIN ANTIBIOTICS | THERAVANCE, INC. (US) | 2003-12-04 | — | — | WO | disclosed |
| US-20030130173-A1 | Cross-linked glycopeptide-cephalosporin antibiotics | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2003-07-10 | — | — | US | disclosed |
| WO-2003031449-A2 | CROSS-LINKED GLYCOPEPTIDE-CEPHALOSPORIN ANTIBIOTICS | THERAVANCE, INC. (US) | 2003-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040033939-A1 | Cross-linked glycopeptide-cephalosporin antibiotics | CSGALNACT1, GYPA, ST3GAL3 | MAPT 4537/4885LMNA 3192/4885GAA 654/4885 |
| US-20030130173-A1 | Cross-linked glycopeptide-cephalosporin antibiotics | CSGALNACT1, GYPA, ST3GAL3 | MAPT 4537/4885LMNA 3192/4885GAA 654/4885 |
| US-20120214967-A1 | CROSS-LINKED GLYCOPEPTIDE-CEPHALOSPORIN ANTIBIOTICS | CSGALNACT1, GYPA, ST3GAL3 | MAPT 4537/4885LMNA 3192/4885GAA 654/4885 |
| US-20100197569-A1 | CROSS-LINKED GLYCOPEPTIDE-CEPHALOSPORIN ANTIBIOTICS | CSGALNACT1, GYPA, ST3GAL3 | MAPT 4487/4885LMNA 3243/4885GAA 670/4885 |
| US-20050239691-A1 | Cross-linked glycopeptide - cephalosporin antibiotics | CSGALNACT1, GYPA, ST3GAL3 | MAPT 4537/4885LMNA 3192/4885GAA 654/4885 |
| US-20050209132-A1 | CROSS-LINKED GLYCOPEPTIDE-CEPHALOSPORIN ANTIBIOTICS | CSGALNACT1, GYPA, ST3GAL3 | MAPT 4537/4885LMNA 3192/4885GAA 654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.